A soluble form of human leukocyte antigen class I antigen (sHLA-I) has been reported to cause apoptosis on cytotoxic T cells and inhibit killer activity of natural killer cells via killer-cell inhibitory receptors. However, its effect on cancer cells has not yet been elucidated. We examined the direct effect of sHLA-I on human liver cancer cell lines, HepG2, HLE and HLF. The effects of sHLA-I on cell growth, DNA synthesis, and apoptosis induction were evaluated. To elucidate the mechanisms, cDNA expression arrays were also examined. sHLA-I caused cell growth inhibition, resulting in apoptosis on human hepatocellular carcinoma, dosedependently. In this process, caspase-3 was activated. sHLA-I also inhibited in vivo growth of hepatocellular carcinoma in severe combined immunodeficient mice. sHLA-I caused apoptosis on human hepatocellular carcinoma.
Introduction
Human leukocyte antigen (HLA) class I antigen is a glycoprotein expressed on the cell membrane, which functions in antigen recognition to CD8-positive cytotoxic T lymphocyte. A soluble form of HLA class I (sHLA-I) has been identified in various bodily fluids (1) (2) (3) (4) . Reports indicate that it increases in an immunologically activated status, e.g. in autoimmune diseases, such as systemic lupus erythematosus (5) and rheumatoid arthritis (6) , as well as after transplantation (7) (8) (9) (10) . The liver is considered to be a major organ for producing sHLA-I (11) . Peripheral blood lymphocytes (PBLs), especially when activated, are also major producers of these molecules (12) .
Zavazava et al have reported that the soluble molecule of HLA class I antigen (sHLA-I) caused apoptosis in primary alloreactive CD8
+ T cells without a second signal (13) . On the other hand, the specific receptor for polymorphic HLA class I antigens, killer-cell inhibitory receptors (KIRs), is expressed on the NK cell, and its signals prevent NK-cellmediated cytotoxicity (14) (15) (16) (17) . The inhibitory MHC class I receptors may appear on T cells only after activation, at which point they are needed to control the extent of an immune reaction.
We have investigated the sHLA-I level in patients with virus-induced liver diseases, such as acute hepatitis, chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma (HCC), and in patients with gastric cancer (18, 19) . The levels of sHLA in patients with liver diseases increased significantly, while those in patients with gastric cancer and HCC were significantly lower than those of normal controls. An increased level of sHLA-I with a liver disorder was considered as a reflection of activated lymphocytes; however, a direct effect of sHLA-I on cancer has not yet been elucidated.
To elucidate this effect, we chose to analyze human liver cancer cell lines, because of the advantages associated with examining the effect of sHLA-I on liver cancer, considering that the liver is assumed to be a major source of circulatory sHLA-I. We examined the direct effect of sHLA-I on the growth of liver cancer cell lines, in vitro and in vivo.
Materials and methods
Preparation of soluble HLA class I antigen. The purification of soluble HLA class I -B7 antigen was performed using an affinity column, according to a modification of the method reported by Hiraki et al (20) . C1R-neo-B7, which was genetically engineered to secrete soluble HLA-B7 antigen, was kindly provided by Professor Carl Grumet, Stanford University. The cell does not have a transmembrane domain in its genetic construction (20) . In brief, a culture supernatant of the cell was collected, followed by ultrafiltration with CENTRIPREP (Amicon, Inc., Beverly, MA), which cut the molecule under 10 kDa. A W6/32 monoclonal antibody for monomorphic HLA class I was bound to a CNBr-activated Sepharose 4B column (Pharmacia, Tokyo, Japan). The ultrafiltrated supernatant was applied to this column and eluted with 0.1 M glycine-NaOH. After neutralization with 0.1 M glycine-HCl, the eluent was dialyzed with phosphatebuffered saline (PBS). Finally, it was ultrafiltrated with ONCOLOGY REPORTS 16: 1375 -1380 , 2006 The soluble form of human leukocyte antigen class I antigen causes apoptosis on hepatocellular carcinoma cell lines CENTRICUT30 (Amicon, Inc.) and used as purified sHLA-I after quantification by an enzyme-linked immunosorbent assay (ELISA) described elsewhere. Growth assay of hepatocellular carcinoma cell line. The liver cancer cell lines, HepG2, HLE and HLF, were provided by the RIKEN cell bank (Tsukuba, Japan). Cell viability was checked by the die-exclusion test using trypan blue. Initially, 7 ml of each cell line, 5x10 4 cells/ml, was cultivated for 2 days under conditions of 5% CO 2 at 37˚C in Dulbecco's modified Eagle's medium (DMEM) with 10% fetal calf serum in a 25-cm 2 culture flask (Corning, Tokyo) with or without the purified sHLA-I. The concentration of the added sHLA-I was 1 μg/ml. As a control, IMDM (Gibco, Tokyo), which was used as a culture medium for C1R-neo-B7, was added at the same concentration as the agent. On the 2nd and 4th day of culture, the cells were removed from the flask using 0.25% trypsin, and the number of cells was counted. Three sets of cultivation were performed, and the mean value ± standard error of mean (SEM) of cell counts was analyzed.
SDS-PAGE
DNA synthesis. HepG2 showed highest sensitivity to sHLA-I, so we used this cell line for further examination. Incorporation of [ 3 H]-thymidine into DNA fraction was measured according to modification of the method reported by Tramontano et al (21) . Two ml of HepG2, 1x10 4 cells/ml, was cultivated for 48 h under conditions of 5% CO 2 at 37˚C in DMEM with 10% FCS in a 24-well microplate (Corning, Tokyo). Then, 1 or 2 μg of the purified sHLA-I, whose concentration had been decided by ELISA, was added. As a control, 2 μl of IMDM (Gibco, Tokyo), which was used as a culture medium for C1R-neo-B7, was added. Cells treated with or without sHLA-I were further cultivated for 24 h after adding 1 μCi/ml of [ 3 H]-thymidine (New England Nuclear, Boston, MA); the specific activity was 6.7 Ci/mmol. Cells were then washed twice with ice-cold PBS, followed by two washes with 5% trichloroacetic acid. The trichloroacetic acid-insoluble material was solublized with a mixture containing 2% Na 2 CO 3 , 0.1% sodium dodecyl sulfate, and 0.1 N NaOH. The solution was then transferred to a vial and neutralized with 50% trichloroacetic acid. Radioactivity was measured in a liquid scintillation counter.
EIA system for the detection of apoptosis. Two ml of HepG2, 1x10 4 /ml, was cultivated for 48 h under 5% of CO 2 at 37˚C in DMEM with 10% FCS on a 24-well microplate. Two μg of the purified sHLA-I was added to the plate, and the cells were cultivated for another 6, 12, 24, and 48 h. Apoptosis in HepG2 was detected by the modified terminal deoxyribonucleotidyl transferase-mediated deoxyuridine triphosphatebiotin nick end labeling (TUNEL) method (22) using enzyme immunoassay. The culture media and cultivated cells exfoliated using 0.25% trypsin at the above-mentioned times were collected into a 15-ml tube and centrifuged. After discarding the supernatant, the cell count was adjusted to 1x10 5 cells/ml of 70% ethyl alcohol. When the analysis was finished, 500 μl of the cell mixture fixed with ethyl alcohol was added to a culture chamber bottomed with a membrane with a 5-μm pore size (Chomotaxicell, Kurabou, Tokyo), topped on a 10-ml tube. To increase the permeability of HepG2, 0.5% Tween-20 was added and held still at room temperature for 30 min after washing three times with 0.01 M PBS. One ml of the reaction mixture: 100 mM sodiumcacodylate, pH 7.0; 1 mM CoCl 2 ; 50 μg/ml gelatin; 10 nmol/ml biotin-16-dUTP (BoehlingerManheim Yamanouchi, Tokyo); 100 U/ml terminal deoxynucleotidyl transferase (Takara Shuzou, Tokyo) was added to the chamber and incubated at 37˚C for 1 h under a humidified condition. After washing three times with 0.01 M PBS, 30X streptavidin-alkalinephosphatase was added and incubated for 1 h at room temperature. After washing with PBS, 100 μl of the substrate was added to the chamber, and 100 μl of a stop buffer (10% sodium dodecyl sulphate and 0.05% EDTA) was added and mixed well. After centrifuging at 3000 rpm, the final product was collected into the tube. Half of it was applied to a 96-well microplate, and optical density at 490 nm was examined using a microplate reader, M-E max (Wako Pure Chemicals, Tokyo). As for the standard curve, HepG2 treated with DNase I (Sigma, St. Louis, MO) at 37˚C for 1 h was applied using the same method.
cDNA expression array. HepG2 was cultivated with the purified sHLA-I (1 μg/ml) at 37˚C for 24 h. HepG2 was also cultivated without sHLA-I as a control. After 24 h of incubation, attached cells were washed twice with PBS. The attached cells were then scraped from the dish. The total RNA was prepared using a Micro-Fast Track 2.0 kit (Invitrogen, Tokyo). The extracted RNA was applied to Atlas cDNA expression arrays (Clontech, Palo Alto, CA) according to the procedure recommended by the manufacturer. In brief, array-specific [ 32 P]-labeled complementary DNA (cDNA) probes were created with reverse transcription. The cDNA probes were hybridized with nylon membranes containing an array of 588 cDNA, and autoradiographs were scanned to identify the patterns of gene expression characteristic of each group. Densitometric analysis was used to standardize the expression of individual genes to a panel of housekeeping controls, and differential gene expression was defined by a signal ratio of at least 2:1.
Western blot analysis. HepG2 was cultivated with the purified sHLA-I (1 μg/ml) at 37˚C for 24 h. HepG2 was also cultivated without sHLA-I as a control. After 24 h of incubation, the attached cells were washed twice with PBS containing 100 μM sodium orthovanadate and lysed with 0.5 ml of M-PER, mammalian protein extraction reagent (Pierce, Rockford, IL). The protein concentration was measured using the BCA protein assay kit (Pierce). The total cellular protein was separated in 4-20% gradient SDS polyacrylamide gel (Daiichi Pure Chemicals, Tokyo) and electroblotted to Hybond-ECL nitrocellulose membranes (Amersham, Tokyo). After being blocked with 5% non-fat dried milk in PBS containing 0.1% Tween-20, the membrane was incubated with a mouse anti-CPP32 (caspase-3) antibody (Oncogenes Research Products, Cambridge, MA). Immunoblot analysis was carried out using an Amersham ECL immunoblot detection system.
Growth inhibition in vivo.
Sub-confluent HepG2 was dispersed by 0.25% trypsin treatment and suspended in a small volume of DMEM with 5% of fetal calf serum. After appropriate dilution, 1x10 5 cells were suspended in 1.0 ml of DMEM containing 1 μg/ml of sHLA-I or PBS as a control and incubated at 37˚C for 1 h. After incubation, 0.1 ml of cell suspension (containing 1x10 4 cells) was directly inoculated into the liver of a severe combined immunodeficient (SCID) mouse (CLEA, Tokyo). The mice were sacrificed 2 weeks after inoculation and evaluated for the presence of hepatic tumors.
Statistics. Statistical analysis of the two groups was carried out using an unpaired-t test. When the P value was <0.05, it was considered to be statistically significant. Fig. 1 shows the result of SDS-PAGE of sHLA-I run on a gradient gel. The 39-kDa form of sHLA-I is visible. This shows that the sHLA-I found here does not have a transmembrane region, whereas the molecular weight of the membranous type of HLA class I antigen is 43 kDa. Breakdown forms of sHLA-I that were smaller than 33 kDa (shown at ~20 kDa) were eliminated by ultrafiltration. The concentration of sHLA-I was measured and used in the following data.
Results

Purity of sHLA-I.
Growth assay of hepatocellular carcinoma. Fig. 2 shows growth curves of hepatocellular carcinoma cell lines cultivated with or without sHLA-I. The growth of cells when cultivated with sHLA-I was inhibited on days 2 and 4, while cells without sHLA-I grew exponentially. There was statistical significance between the cell count with sHLA-I and that without sHLA-I on the fourth day (P<0.05). HepG2 showed highest sensitivity to sHLA-I-induced growth inhibition, so we chose this cell line for further examinations.
DNA synthesis. Fig. 3 shows the [ 3 H]-thymidine incorporation of HepG2 when cultivated with or without sHLA-I administration. HepG2 without sHLA-I showed 1,014,256±1,953 cpm, while that with 1 μg/ml of sHLA-I showed 79,502±3,641 cpm and that with 2 μg/ml of sHLA-I showed 55,582±5,208 cpm. There was statistical significance between the control and 1 μg/ ml of sHLA-I addition (P<0.05), the control and 2 μg/ml of sHLA-I addition (P<0.01), and 1 μg/ml of sHLA-I addition and 2 μg/ml of sHLA-I addition (P<0.05). Thus, sHLA-I inhibited the growth of HepG2 dose-dependently. EIA system for apoptosis. Fig. 4 shows the result of EIA for the detection of apoptosis. The left column of Fig. 4 shows the standard curve of this system. The standard curve was obtained by treating cells with DNase as described in the Materials and methods. The result shows that, when sHLA-I was added to the culture medium, HepG2 was led to apoptosis. No apoptosis occurred in the control (P<0.05).
cDNA expression array. The cDNA expression array showed higher expression of · 1 catenin, serine kinase, tyrosine kinase receptor, and DCC precursor (Fig. 5) . DCC has been reported to cause G2/M arrest/apoptosis (23, 24) , however, there is no significant difference of DCC expression between sHLA-Itreated cells and controls by Western blotting. There are so many kinds of serine kinases and tyrosine kinase receptors that we could not confirm which one is the key molecule in the mechanism of growth inhibition in this study. To elucidate the molecules associated with the mechanism that causes apoptosis on HepG2, we performed Western blot analysis on caspase-3 and CD95 (Fas).
Western blotting. Fig. 6 shows Western blot analysis of caspase-3 (CPP32). In the group treated with sHLA-I, caspase-3 showed a breakdown form, which represented an activation of caspase-3. In the control group, a band at 32 kDa was shown; however, there was no breakdown form of caspase-3. Table I shows the result of intrahepatic tumor progression of HepG2 inoculated into SCID mice. HepG2 when incubated with sHLA-I showed no tumor growth, even on microscopic analysis (data not shown), while, in the control group, every mouse had a hepatic tumor at 2 weeks after inoculation. All organs of mice used in this study were examined; however, there was no distant metastasis in either group. Table I . The result of intrahepatic tumor progression of HepG2 inoculated into SCID mice.
Growth inhibition in vivo.
HepG2 was suspended in DMEM containing 1 μg/ml of sHLA-I for 1 h. b HepG2 of control group was suspended in DMEM without sHLA-I. (25) . The role of an alternative splicing form, 39 kDa in molecular weight, has not yet been elucidated. sHLA-I has been reported to inhibit the killer activity of the NK cell by binding to the KIRs (14) (15) (16) (17) . It also causes apoptosis on the alloreactive CD8 + T cell (10, 13, (26) (27) (28) . The levels of sHLA-I in some inflammatory diseases have been reported to be attenuated. Thus, the alternative splicing form excreted outside the cells plays some role in controlling the extent of the immune reaction. Whereas many reports have discussed the relationship between sHLA-I and the immune reaction (5-10), only a few have discussed its biological significance in malignancy (19, 29) . We have reported that the level of sHLA-I in far-advanced gastric cancer patients was significantly lower than that in a normal control and in the early stages of cancer (19) . It is assumed that sHLA-I plays some role in the immune system against tumor cells. Therefore, we estimated that sHLA-I might have a certain direct effect on cancer cells. To assess the direct effect of sHLA-I on the growth of cancer cells, we selected human hepatocellular carcinoma cell lines, because the liver is assumed to be the major producer of sHLA-I.
In the present study, sHLA-I caused the growth inhibition of hepatocellular carcinoma cell lines in a dose-dependent manner. The apoptosis of cytotoxic T cells caused by sHLA-I also occurred without CD95 activation (13) . Many pathways have been reported to cause apoptosis. Therefore, we also examined cDNA expression arrays of HepG2 when incubated with sHLA-I. The expression of · 1 catenin, serine kinase, tyrosine kinase receptor, and DCC precursor was shown to be higher in the array than in the control; however, we could not confirm which molecule caused this apoptosis.
In chronic liver disease or liver cirrhosis, the sHLA-I level was significantly higher than that of the normal control, but it was lower in HCC than in hepatitis and cirrhosis (18) . In patients with chronic hepatitis, recurrence of HCC has been reported to be less frequent than in cirrhotic liver. A more aggressive pre-cancerous state and a longer period of persistent inflammation should cause recurrence of HCC; however, a decreased level of sHLA-I should permit the growth of a hepatocellular carcinoma cell.
Concerning clinical applications, there are some problems to be overcome. sHLA-I has many alleles, as do the membranous HLA class I antigens. Before sHLA-I is injected into a patient, the type of HLA-I should be checked, and a suitable sHLA-I should be produced. If the inhibitory mechanism were more precisely elucidated, we could synthesize a peptide motif that causes the same effect without causing antigenesity. sHLA-I might have an amazing effect on human cancer cell lines, especially on HepG2; therefore, vigorous research should be pursued to elucidate the mechanisms causing growth inhibition and apoptosis by sHLA-I.
